




# **1<sup>st</sup> Nordic Status Epilepticus Meeting** **Bergen, 27-28 May 2021**

Norway

The meeting is financially supported by Desitin.

# Speakers and chairpersons



## Andrea Rossetti

is Head of the EEG/epileptology unit at the Neurology Department of the CHUV (Lausanne University Hospital, Switzerland). His research has focused over several years upon nosology, diagnosis and treatment of status epilepticus; further interests are coma prognostication and pharmacological treatment of epilepsy.




## Hannah Cock

Prof. Cock is professor of Epilepsy & Medical Education at St George's University of London, where she is also the course lead for undergraduate medicine. Her primary research interest has been in status epilepticus including early pre-clinical work, invited faculty at all of the Biannual International Status Epilepticus Colloquium meetings since 2007, membership of the ILAE status epilepticus Classification task force, and most recently as a member of the executive team on the NIH (USA) NINDS Established Status Epilepticus Treatment Trial (2014-19).



## Sándor Beniczky

Sándor Beniczky is board-certified neurologist, clinical neurophysiologist and epileptologist. He is professor at Aarhus University Hospital, and he is the Head of the Clinical Neurophysiology Department at the Danish Epilepsy Centre. He is the chair of the joint EEG taskforce of the IFCN and ILAE, member of the ILAE commission on diagnostic methods, ILAE education council and the executive committee of ILAE-Europe. He is editor-in-chief of *Epileptic Disorders*. The main research interest of Dr. Beniczky is EEG and epilepsy, focusing on electromagnetic source imaging, seizure detection, standardisation and quality-assurance in clinical neurophysiology. He has supervised eight Ph.D. students. He is author of 154 peer-reviewed papers and 22 book chapters.



## Monika Mochol

PhD student, working as a consultant at the Østfold Hospital Trust. She is investigating the presence and role of immunological mechanisms in epilepsy patients.



## Ketil Berg Olsen

Senior Consultant in Neurology and Clinical Neurophysiology, Østfold Hospital Trust and Oslo University Hospital, Rikshospitalet. Member of ERGO, Epilepsy Research Group of Oslo. Many years experience in epileptology/neurology/clinical neurophysiology, about 5 years experience in SEEG and IOM.



## Ellen Molteberg

MD, Neurologist and Head of the Adult Department at the National Center for Epilepsy in Norway. Special interest in non-medical treatment, i.e modified Atkins diet for adult patients.



## Jon Barlinn

MD Senior consultant in Child Neurology Department of Pediatrics and Adolescent Medicine, Oslo University Hospital. The Child Neurology section at our hospital is treating super refractory epilepsy as a referral center. Ketogenic diet is one of our treatment modalities.



## Gro Anita Gauslå

specialist in paediatric, working as a consultant at Department of Paediatric Neurology, OUS, Ullevål. Member of ERGO (Epilepsy Research Group of Oslo). Director Norwegian Headache Association.



## Toni Berger

MD, PhD student, Department of Neurology, Oslo University Hospital - Rikshospitalet, Oslo, Norway. After working one year in the Department of Neurology, Østfold hospital trust, he joined ERGO (Epilepsy Research Group of Oslo in Department of Neurology, OUS-RH) in 2017. His PhD is financed by a Marie-Curie scholarship as part of the "EU Glia PhD" project - a European network for brain research.



## Erik Taubøll

Professor of Neurology and Senior Consultant, Department of Neurology, Oslo University Hospital - Rikshospitalet, Oslo, Norway. Head of ERGO, Epilepsy Research Group of Oslo, in Department of Neurology. The group is active in both clinical, translational and basic epilepsy research, see: <https://www.ous-research.no/ergo/>




## Bernt Engelsen

Born 1951. Professor of Neurology since 1989. Research background; neurotransmission research on glutamate in the 1980ies-90ies, and since 1994 head of the clinical epilepsy unit at Haukeland University Hospital. Research interest; clinical epileptology, POLG related epilepsy and Status epilepticus.



## Line Bédos Ulvin

is a neurologist and clinical neurophysiologist working at Oslo University Hospital. Her field of interest is epilepsy and EEG, and she is involved in several research projects on status epilepticus.



## Anette Storstein

MD PhD, is a consultant of neurology and vice chair of the Department of Neurology at Haukeland University Hospital. Her clinical and scientific focus is on neuroimmunology/neuro-oncology and neurodegenerative diseases. As Chair of the Norwegian Brain Council, she works to improve and promote neuroscience and brain health issues.



## Morten Horn

MD, PhD, is a consultant in neurology at Oslo University Hospital. He is a lecturer in medical ethics at the University of Oslo, and a member of the Medical Ethics Council for the Norwegian Medical Association.



## Sarah Folkestad Habhab

MD, Medical Intern, Herlev Hospital, Denmark. She wrote her master thesis in collaboration with ERGO (Epilepsy Research Group of Oslo), on the phenomenon of ammonia increase after intravenous valproic acid in a status epilepticus cohort, and the impact of ammonia levels on treatment decisions.



## Kjell Heuser

(MD, PhD) is Senior Consultant in Neurology and Researcher in Department of Neurology, Oslo University Hospital. He is a Clinical Epileptologist, and active member of ERGO (Epilepsy Research Group of Oslo), with special interest in translational epilepsy research with the main focus on glia dysfunction in epilepsy.



## Kjersti Nesheim Power

is a neurologist with a PhD in cognitive consequences of status epilepticus. She is a member of Bergen Epilepsy Research Group and works at Department of Neurology at Haukeland University Hospital.



## Christian Samsonsen

Head of Department/neurologist, Department of Neurology and Clinical Neurophysiology, St Olav's hospital Associate professor, INB, NTNU. Special fields of interest: Clinical epileptology, seizure precipitants.



# Program

## Day 1

09.30 Opening, *Erik Taubøll*

### Definitions, mechanisms and diagnostic monitoring – chair Bernt Engelsen

09.40-10.00 Definitions, incidence and etiology. *Hannah Cock*

10.00-10.20 Basic mechanisms for epileptogenesis and development of SE. *Toni Berger*

10.20-11.00 What is the role of EEG in SE? *Sándor Beniczky*

11.00-11.20 Continuous versus repeated routine EEG in critically ill adults with altered consciousness – the CERTA study. *Andrea Rossetti*

11.20-11.40 Discussion

11.40-12.40 **LUNCH**

### Treatment of SE – chair Erik Taubøll

12.40-13.00 First line: The Norwegian guidelines for first-line treatment. *Ketil Berg Olsen*

13.00-13.40 Second line: Which AED to choose when first line SE treatment fails? *Hannah Cock*

13.40-14.20 Third line: Refractory and superrefractory SE - which therapeutic strategy to choose when standard treatment does not work? *Andrea Rossetti*

14.20-14.40 Discussion

14.40-15.00 **Coffee break**

### When backs are against the wall: The Norwegian experience with non-standardized treatments – chair Kjell Heuser

15.00-15.20 Ketogenic diet. *Jon Barlinn*

15.20-15.35 Case report - the use of an interleukin 1 $\beta$  antagonist-Anakinra. *Monika Mochol*

15.35-15.50 Pyridoxine in SE treatment – a case report. *Ellen Molteberg*

15.50-16.05 The sad story of neurosteroids in SE – what can we learn from it? *Erik Taubøll*

16.05-16.25 **Coffee break**

### SE in special syndromes and conditions – chair Ellen Molteberg

16.25-16.50 Autoimmune refractory epilepsy and SE. *Anette Storstein*

16.50-17.05 Discussion

17.05-17.25 FIRES/NORSE. *Gro Anita Gauslå*

17.25-17.35 Discussion

17.35-17.50 Hyperammonemia after VPA in SE – a clinical problem?  
*Sarah Habhab*

17.50-18.00 Discussion

18.00 *End of Day 1, closing remarks, Erik Taubøll*

## Day 2

### Consequences of SE and ethical considerations – chair Christian Samsonsen

08.15-08.40 Cognitive sequelae after SE. *Kjersti Nesheim Power*

08.40-09.00 Prediction of outcome. *Line Bédos Ulvin*

09.00-09.25 Ethical issues - when to stop SE treatment. *Morten Horn*

09.25-09.45 Closing remarks. What is the way forward in Norway?  
The need for a national SE registry. *Erik Taubøll*



# Organising Committee:



**Erik Taubøll**  
**(Head of organising committee)**  
*Professor of Neurology and Senior Consultant, Department of Neurology, Oslo University Hospital - Rikshospitalet, Oslo, Norway. Head of ERGO, Epilepsy Research Group of Oslo, in Department of Neurology. The group is active in both clinical, translational and basic epilepsy research, see: <https://www.ous-research.no/ergo/>*



**Kjell Heuser**  
*(MD, PhD) is Senior Consultant in Neurology and Researcher in Department of Neurology, Oslo University Hospital. He is a Clinical Epileptologist, and active member of ERGO (Epilepsy Research Group of Oslo), with special interest in translational epilepsy research with the main focus on glia dysfunction in epilepsy.*



**Ketil Berg Olsen**  
*Senior Consultant in Neurology and Clinical Neurophysiology, Østfold Hospital Trust and Oslo University Hospital, Rikshospitalet. Member of ERGO, Epilepsy Research Group of Oslo. Many years experience in epileptology/neurology/clinical neurophysiology, about 5 years experience in SEEG and IOM.*



**Morten Horn**  
*MD, PhD, is a consultant in neurology at Oslo University Hospital. He is a lecturer in medical ethics at the University of Oslo, and a member of the Medical Ethics Council for the Norwegian Medical Association.*



**Ellen Molteberg**  
*MD, Neurologist and Head of the Adult Department at the National Center for Epilepsy in Norway. Special interest in non-medical treatment, i.e modified Atkins diet for adult patients.*



**Line Bédos Ulvin**  
*is a neurologist and clinical neurophysiologist working at Oslo University Hospital. Her field of interest is epilepsy and EEG, and she is involved in several research projects on status epilepticus.*



**Christian Samsonsen**  
*Head of Department/neurologist, Department of Neurology and Clinical Neurophysiology, St Olav's hospital Associate professor, INB, NTNU. Special fields of interest: Clinical epileptology, seizure precipitants.*



**Bernt Engelsen**  
*Born 1951. Professor of Neurology since 1989. Research background; neurotransmission research on glutamate in the 1980ies-90ies, and since 1994 head of the clinical epilepsy unit at Haukeland University Hospital. Research interest; clinical epileptology, POLG related epilepsy and Status epilepticus.*



**Kjersti Nesheim Power**  
*is a neurologist with a PhD in cognitive consequences of status epilepticus. She is a member of Bergen Epilepsy Research Group and works at Department of Neurology at Haukeland University Hospital.*



**Gro Ellen Albrigtsen**  
*Cand. Scient. Physiology, NTNU, Sales and Marketing Manager CNS, Desitin Pharma*

